Alimera Sciences Inc.

NASDAQ:ALIM   3:59:51 PM EDT
5.50
+0.22 (+4.17%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)38.16M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$13.41 Million
Adjusted EPS-$0.42
See more estimates
10-Day MA$5.54
50-Day MA$4.86
200-Day MA$7.81
See more pivots

Alimera Sciences Inc. Stock, NASDAQ:ALIM

6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30005
United States of America
Phone: +1.678.990.5740
Number of Employees: 140

Description

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.